• English
    • íslenska
  • English 
    • English
    • íslenska
  • Login
View Item 
  •   Home
  • Journal Articles, Peer Reviewed (Ritrýndar vísindagreinar)
  • English Journal Articles (Peer Reviewed)
  • View Item
  •   Home
  • Journal Articles, Peer Reviewed (Ritrýndar vísindagreinar)
  • English Journal Articles (Peer Reviewed)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browse

All of HirslaCommunitiesAuthorsTitleSubjectsSubject (MeSH)Issue DateJournalThis CollectionAuthorsTitleSubjectsSubject (MeSH)Issue DateJournal

My Account

LoginRegister

Local Links

FAQ - (Icelandic)FAQ - (English)Hirsla LogosAbout LandspitaliLSH Home PageLibrary HomeIcelandic Journals

Statistics

Display statistics

Golimumab in the treatment of psoriatic arthritis.

  • CSV
  • RefMan
  • EndNote
  • BibTex
  • RefWorks
Average rating
 
   votes
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item. When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
 
Your vote was cast
Thank you for your feedback
Authors
Love, Thorvardur Jon
Kavanaugh, Arthur
Issue Date
2018-11-01

Metadata
Show full item record
Citation
Golimumab in the treatment of psoriatic arthritis. 2018, 14(11):893-898 Expert Rev Clin Immunol
Abstract
Psoriatic arthritis (PsA) is an inflammatory arthritis that can be aggressive and destructive, resulting in significant morbidity. While many new agents have been approved for the treatment of PsA over the past decade, TNF inhibitors (TNFi)remain an anchor treatment, in part based on extensive clinical experience. Recently, the TNFi golimumab was approved for intravenous use in PsA. Areas covered: This expert review presents an overview of the currently available treatment options for PsA with a focus on the evidence from clinical trials supporting the use of golimumab in PsA. This information is placed in context with recent advances in the understanding of PsA pathogenesis and treatment. Expert commentary: The rapid growth of treatment options available for PsA has brought the prospect of personalized treatment selection closer to reality but improved understanding of the domains of PsA and new biomarkers may be needed before such changes reach the clinic. Until patients who are most likely to benefit from a given agent can be identified and then treated accordingly, TNFi will likely remain a central option and their further development, such as the introduction of an intravenous form of golimumab, remains an important part of treatment improvement.
Description
To access publisher's full text version of this article click on the hyperlink below
Additional Links
https://www.tandfonline.com/doi/abs/10.1080/1744666X.2018.1524755?journalCode=ierm20
ae974a485f413a2113503eed53cd6c53
10.1080/1744666X.2018.1524755
Scopus Count
Collections
English Journal Articles (Peer Reviewed)

entitlement

Related articles

  • Tumor necrosis factor inhibitors in psoriatic arthritis.
  • Authors: Mantravadi S, Ogdie A, Kraft WK
  • Issue date: 2017 Aug
  • Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.
  • Authors: Caso F, Cantarini L, Morisco F, Del Puente A, Ramonda R, Fiocco U, Lubrano E, Peluso R, Caso P, Galeazzi M, Punzi L, Scarpa R, Costa L
  • Issue date: 2015 May
  • TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
  • Authors: Tobin AM, Kirby B
  • Issue date: 2005
  • The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
  • Authors: Rotar Ž, Tomšič M, Praprotnik S, Slovenian Rheumatologists.
  • Issue date: 2019 Feb
  • Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis.
  • Authors: Chandran V, Shen H, Pollock RA, Pellett FJ, Carty A, Cook RJ, Gladman DD
  • Issue date: 2013 Jun

DSpace software (copyright © 2002 - 2021)  DuraSpace
Quick Guide | Contact Us
Open Repository is a service operated by 
Atmire NV
 

Export search results

The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.